Comparison of Treatment Efficacy in Paroxysmal Atrial Fibrillation

Трегубов, В. Г.; Eremina, Marina A.; Канорский, С. Г.; Покровский, В. М.

doi:10.15829/1728-8800-2017-2-46-51

Kardiovask. ter. profil.

2017

DOI: 10.15829/1728-8800-2017-2-46-51

|View full text |Cite

Comparison of Treatment Efficacy in Paroxysmal Atrial Fibrillation

В. Г. Трегубов¹,

Marina A. Eremina²,

С. Г. Канорский³

et al.

Abstract: ФГБОУ ВО Кубанский государственный медицинский университет Минздрава России. Краснодар, Россия Цель. Сравнить эффективность терапии небивололом (Нб) или соталолом (Ст) у пациентов с пароксизмальной формой фибрилляции предсердий (ФП) на фоне гипертонической болезни (ГБ) и/или ишемической болезни сердца (ИБС), учитывая их влияние на регуляторно-адаптивный статус (РАС). Материал и методы. В исследовании участвовали 60 пациентов с пароксизмальной формой ФП на фоне ГБ II-III стадий и/или ИБС, рандомизированных в дв… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2020

2021

Publication Types

Select...

Article3

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

References 4 publications

(4 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

Assessment of the effect of nebivolol and сarvedilol on the functional state of patients with diastolic chronic heart failure

et al. 2021

View full text Add to dashboard Cite

Aim. To determine the effect of combined therapy with nebivolol or carvedilol on the functional state of patients with diastolic chronic heart failure (CHF). Material and methods. The study involved 68 patients with CHF and preserved left ventricular ejection fraction, who were randomized into two groups for treatment with bisoprolol or carvedilol. As part of the combination therapy was prescribed quinapril, and if indicated atorvastatin, acetylsalicylic acid in the intestinal soluble shell. Initially and after 24 weeks of therapy were carried out: quantitative assessment of regulatory-adaptive status (RAS), echocardioscopy, treadmill test, six-minute walking test, subjective assessment of quality of life, determination of level of N-terminal fragment of the brain natriuretic peptide precursor in blood plasma. Results. Both schemes of combined therapy comparably improved the morpho-functional parameters of the heart and quality of life. In comparison with carvedilol, nebivolol more pronouncedly increased RAS and tolerance to physical activity. Conclusion. In patients with diastolic CHF in combination therapy, the use of nebivolol, in comparison with carvedilol, may be preferable due to the positive effect on the functional state.

show abstract

Assessment of the effect of nebivolol and сarvedilol on the functional state of patients with diastolic chronic heart failure

et al. 2021

View full text Add to dashboard Cite

show abstract

Eff ect of nebivolol and carvedilol on the functional state of patients with chronic heart failure and preserved left ventricular ejection fraction

Трегубов

Khilkevich

Shubitidze³

et al. 2021

jour

View full text Add to dashboard Cite

Objective. Compare the eff ect of combination therapy with nebivolol or carvedilol on the functional state of patients with chronic heart failure (CHF) and preserved ejection fraction (pEF) of the left ventricle (LV). Material and methods. The study involved 80 patients with diastolic CHF, who were randomized into two groups. In group I was appointed of nebivolol (7.7 ± 2.4 mg/day, n = 40), in group II — carvedilol (30.5 ± 8.7 mg/day, n = 40). As part of the combination therapy, quinapril was prescribed (13.7 ± 2.7 mg/day, n = 40 and 13.5 ± 2.6 mg/day, n = 40), and if indicated — atorvastatin (15.3 ± 4.6 mg/day, n = 17 and 16.2 ± 5.2 mg/day, n = 17) and acetylsalicylic acid in the intestinal soluble shell (96.4 ± 13.4 mg/day, n = 14 and 93.8 ± 13.3 mg/day, n = 13), respectively. Initially and after 6 months of therapy were carried out: quantitative assessment of regulatory-adaptive status (RAS) (by means of a sample of cardiac-respiratory synchronism), echocardioscopy, treadmill test, test with a six-minute walk, subjective assessment of quality of life, determination of the level of the N-terminal fragment of the brain natriuretic peptide in blood plasma, daily monitoring of blood pressure. Results. Both schemes of combined therapy comparably improved the structural and functional state of the heart, controlled arterial hypertension. In comparison with carvedilol, nebivolol diff ered positive eff ect on the RAS, more increased tolerance to physical activity and improved quality of life. Conclusion. In patients with CHF pEF LV in combination therapy, the use of nebivolol, in comparison with carvedilol, may be preferable due to the more pronounced positive eff ect on the functional state.

show abstract

Determination of the Impact of Bisoprolol and Сarvedilol on Regulatory-Adaptive Status of Patients With Chronic Heart Failure and Preserved Left Ventricular Fraction

Трегубов

Khilkevich

Shubitidze

et al. 2020

Evrazijskij kardiologičeskij žurnal

View full text Add to dashboard Cite

Objective. To determine the effect of bisoprolol or carvedilol therapy on the regulatory-adaptive status (RAS) of patients with chronic heart failure (CHF) and preserved ejection fraction (pEF) of the left ventricle (LV) the background of hypertensive disease (HD).Material and methods. The study involved 68 patients with CHF and pEF of the LV, who were randomized into two groups for treatment with bisoprolol (7,3±2,4 mg/day, n=34) and carvedilol (28,4±12,3 mg/day, n=34). As part of the combination therapy, quinapril was prescribed (13,5±2,5 mg/ day, n=34 and 12,6±2,9 mg/day, n=34), and if indicated – atorvastatin (16,3±5,0 mg/day, n=11 and 15,5±5,2 mg/day, n=11) and acetylsalicylic acid in the intestinal soluble shell (93,8±17,7 mg/day, n=8 and 94,4±15,8 mg/day, n=8), respectively. Initially and after 6 months of therapy were carried out: quantitative assessment of RAS (by means of a sample of cardiac-respiratory synchronism), treadmill test, six-minute walking test, subjective assessment of quality of life, determination of the level of N-terminal fragment of brain natriuretic peptide, echocardioscopy, daily monitoring of blood pressure.Results. Both regimens of combined drug therapy had comparable cardioprotective, hypotensive and neuromodulating effects, equally increased exercise tolerance. In comparison with bisoprolol, carvedilol differed positive impact on RAS, improved quality of life more.Conclusion. In patients with CHF and pEF LV in combination therapy, the use of carvedilol, in comparison with bisoprolol, may be preferable due to the positive effect on the RAS.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Comparison of Treatment Efficacy in Paroxysmal Atrial Fibrillation

Cited by 3 publications

References 4 publications

Assessment of the effect of nebivolol and сarvedilol on the functional state of patients with diastolic chronic heart failure

Assessment of the effect of nebivolol and сarvedilol on the functional state of patients with diastolic chronic heart failure

Eff ect of nebivolol and carvedilol on the functional state of patients with chronic heart failure and preserved left ventricular ejection fraction

Determination of the Impact of Bisoprolol and Сarvedilol on Regulatory-Adaptive Status of Patients With Chronic Heart Failure and Preserved Left Ventricular Fraction

Contact Info

Product

Resources

About